Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fehm

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2012
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patientsE-F Solomayer, G Gebauer, P Hirnle, et al.
Clinical Pharmacology and Therapeutics|April 1, 2011
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasmaT E Mürdter, W Schroth, L Bacchus-Gerybadze, et al.
Oncogene|December 14, 2011
MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathwaysI Keklikoglou, C Koerner, C Schmidt, et al.
Breast Cancer Research and Treatment|March 16, 2013
The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapseA D Hartkopf, M Banys, F Meier-Stiegen, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|August 8, 2015
[Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation]M Beckmann, C Sell, M Aydogdu, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|July 30, 2016
[Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation]M W Beckmann, C Sell, M Aydogdu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2010
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trialG von Minckwitz, H Eidtmann, S Loibl, et al.
Translational Oncology|May 29, 2021
ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processingH Asperger, J-P Cieslik, B Alberter, et al.
Clinical & Experimental Metastasis|October 17, 2018
Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST)C Liedtke, Hans-Christian Kolberg, L Kerschke, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|November 30, 2010
[Are breast biopsies adequately funded? A process cost & revenue analysis]M Hahn, E Fischbach, T Fehm, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2012
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patientsE-F Solomayer, G Gebauer, P Hirnle, et al.
Clinical Pharmacology and Therapeutics|April 1, 2011
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasmaT E Mürdter, W Schroth, L Bacchus-Gerybadze, et al.
Oncogene|December 14, 2011
MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathwaysI Keklikoglou, C Koerner, C Schmidt, et al.
Breast Cancer Research and Treatment|March 16, 2013
The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapseA D Hartkopf, M Banys, F Meier-Stiegen, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|August 8, 2015
[Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation]M Beckmann, C Sell, M Aydogdu, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|July 30, 2016
[Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation]M W Beckmann, C Sell, M Aydogdu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2010
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trialG von Minckwitz, H Eidtmann, S Loibl, et al.
Translational Oncology|May 29, 2021
ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processingH Asperger, J-P Cieslik, B Alberter, et al.
Clinical & Experimental Metastasis|October 17, 2018
Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST)C Liedtke, Hans-Christian Kolberg, L Kerschke, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|November 30, 2010
[Are breast biopsies adequately funded? A process cost & revenue analysis]M Hahn, E Fischbach, T Fehm, et al.
Pageof 10